A detailed history of Rice Hall James & Associates, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Rice Hall James & Associates, LLC holds 117,417 shares of NBIX stock, worth $14.7 Million. This represents 0.8% of its overall portfolio holdings.

Number of Shares
117,417
Previous 118,105 0.58%
Holding current value
$14.7 Million
Previous $16.3 Million 16.86%
% of portfolio
0.8%
Previous 1.06%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$114.58 - $153.15 $78,831 - $105,367
-688 Reduced 0.58%
117,417 $13.5 Million
Q2 2024

Aug 07, 2024

SELL
$130.86 - $143.19 $1.09 Million - $1.19 Million
-8,316 Reduced 6.58%
118,105 $16.3 Million
Q1 2024

Apr 23, 2024

SELL
$130.4 - $143.74 $678,080 - $747,448
-5,200 Reduced 3.95%
126,421 $17.4 Million
Q4 2023

Feb 08, 2024

SELL
$106.07 - $132.76 $62,793 - $78,593
-592 Reduced 0.45%
131,621 $17.3 Million
Q3 2023

Nov 02, 2023

SELL
$94.02 - $117.1 $268,615 - $334,554
-2,857 Reduced 2.12%
132,213 $14.9 Million
Q2 2023

Jul 24, 2023

SELL
$89.53 - $104.87 $194,011 - $227,253
-2,167 Reduced 1.58%
135,070 $12.7 Million
Q1 2023

May 11, 2023

SELL
$94.11 - $123.02 $1.14 Million - $1.49 Million
-12,130 Reduced 8.12%
137,237 $13.9 Million
Q4 2022

Jan 27, 2023

SELL
$106.72 - $127.06 $379,069 - $451,317
-3,552 Reduced 2.32%
149,367 $0
Q3 2022

Nov 01, 2022

SELL
$92.03 - $107.81 $4.57 Million - $5.35 Million
-49,627 Reduced 24.5%
152,919 $16.2 Million
Q2 2022

Aug 08, 2022

SELL
$75.79 - $100.07 $319,000 - $421,194
-4,209 Reduced 2.04%
202,546 $19.7 Million
Q1 2022

May 05, 2022

BUY
$72.45 - $94.81 $9.91 Million - $13 Million
136,782 Added 195.48%
206,755 $19.4 Million
Q4 2021

Feb 14, 2022

SELL
$79.65 - $106.22 $641,341 - $855,283
-8,052 Reduced 10.32%
69,973 $5.96 Million
Q3 2021

Nov 09, 2021

SELL
$86.18 - $99.03 $450,807 - $518,025
-5,231 Reduced 6.28%
78,025 $7.48 Million
Q2 2021

Jul 29, 2021

SELL
$89.43 - $102.27 $1,252 - $1,431
-14 Reduced 0.02%
83,256 $8.1 Million
Q1 2021

May 14, 2021

SELL
$87.57 - $119.4 $336,969 - $459,451
-3,848 Reduced 4.42%
83,270 $8.1 Million
Q4 2020

Feb 16, 2021

BUY
$86.91 - $108.33 $1.12 Million - $1.4 Million
12,938 Added 17.44%
87,118 $8.35 Million
Q3 2020

Nov 16, 2020

BUY
$96.16 - $135.15 $878,902 - $1.24 Million
9,140 Added 14.05%
74,180 $7.13 Million
Q2 2020

Aug 14, 2020

SELL
$85.09 - $130.36 $84,494 - $129,447
-993 Reduced 1.5%
65,040 $7.94 Million
Q1 2020

May 15, 2020

SELL
$75.11 - $113.76 $61,890 - $93,738
-824 Reduced 1.23%
66,033 $5.72 Million
Q4 2019

Jan 29, 2020

BUY
$86.8 - $118.57 $465,421 - $635,772
5,362 Added 8.72%
66,857 $7.19 Million
Q3 2019

Oct 30, 2019

SELL
$83.82 - $101.5 $54,818 - $66,381
-654 Reduced 1.05%
61,495 $5.54 Million
Q2 2019

Aug 01, 2019

SELL
$72.24 - $91.27 $836,177 - $1.06 Million
-11,575 Reduced 15.7%
62,149 $5.25 Million
Q1 2019

May 01, 2019

BUY
$69.31 - $91.53 $2.08 Million - $2.74 Million
29,983 Added 68.55%
73,724 $6.5 Million
Q4 2018

Feb 14, 2019

BUY
$68.32 - $124.36 $2.99 Million - $5.44 Million
43,741 New
43,741 $3.12 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Rice Hall James & Associates, LLC Portfolio

Follow Rice Hall James & Associates, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rice Hall James & Associates, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rice Hall James & Associates, LLC with notifications on news.